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Acute Liver Failure (ALF) in Pregnancy: 
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BaCKgRoUND aND aIMS: Acute liver failure (ALF), 
characterized by sudden onset of coagulopathy (international 
normalized ratio [INR]  ≥  1.5) and encephalopathy, may occur 
during pregnancy either as a pregnancy-associated etiology 
or an unrelated and coincidental liver injury. The U.S. Acute 
Liver Failure Study Group, comprised of 33 tertiary care liver 
centers, has enrolled consecutive patients with ALF or acute 
liver injury (ALI; INR  ≥  2.0 with no encephalopathy), over 
two decades.
appRoaCH aND ReSUltS: Etiologies, clinical features, 
and outcomes of 70 of 3,155 patients (2.2%) who developed 
ALF or ALI during pregnancy were reviewed to determine 
how many were pregnancy associated (pregnancy-associated 
liver disease; PAALD) and how many were attributed to other 
etiologies. Thirty-five of the 70 were considered PAALD, of 
whom nearly half were attributed to hemolysis, elevated liver 
enzymes, and low platelets (HELLP) syndrome and half to 
acute fatty liver of pregnancy (AFLP), although, in some in-
stances, the distinction was unclear. Virtually all with PAALD 
had been delivered before hepatology referral, mostly by ce-
sarean section. Acetaminophen toxicity accounted for 21 (60% 
of the remaining cases), with the remainder resulting from 
a variety of other causes, but not including viral hepatitis 
A through E. Although recovery with delivery or supportive 
measures was possible in most cases, 11 of 70 (16%) required 
liver transplantation and 8 (11%) died. Swansea criteria to di-
agnose AFLP were met by all patients with PAALD and also 
by virtually all women with other forms of ALF.
CoNClUSIoNS: Only half of those with ALF during 
pregnancy appeared to have HELLP or AFLP. Morbidity and 
mortality for mother and fetus are strongly associated with 
etiology of liver failure. (Hepatology 2020;72:1366-1377).
Acute liver failure (ALF) is a rare condition, affecting approximately 2,000-3,000 patients annually in the United States.(1) ALF occur-
ring in pregnancy is associated with significant mater-
nal and fetal morbidity and mortality.(2,3) Certain liver 
conditions that lead to ALF, such as hemolysis, ele-
vated liver enzymes, low platelets (HELLP) syndrome 
and acute fatty liver of pregnancy (AFLP), are limited 
solely to pregnant women, occur during the third tri-
mester, and can be classified as pregnancy-associated 
acute liver diseases (PAALDs).(4-6) In the obstetri-
cal literature, diagnostic criteria for AFLP, known as 
the Swansea criteria, have been proposed as a means 
to distinguish AFLP from other causes of liver dys-
function, including HELLP, but these have not been 
extensively validated.(7,8)
Not all ALF that occurs during pregnancy is directly 
related to the pregnancy itself. For example, certain viruses 
occur relatively frequently in the reproductive years; 
likewise, pregnant women may be more susceptible to 
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conditions not specifically pregnancy related, such as herpes 
simplex virus (HSV) infection.(9-11) The U.S. Acute Liver 
Failure Study Group (ALFSG) registry has prospectively 
collected detailed demographic, clinical, and biochemical 
information on >3,100 patients admitted to tertiary care 
hospitals over two decades, including those presenting with 
full-blown ALF (defined as any degree of encephalopa-
thy and coagulopathy with international normalized ratio 
[INR] ≥ 1.5) and those with acute liver injury (ALI; severe 
injury with INR of ≥2.0, but without encephalopathy).(12) 
To better understand and manage future pregnant women 
with ALF/ALI, clinical features and outcomes of all 
pregnant women enrolled in the ALFSG registry that met 
the standard entry criteria for ALF/ALI were reviewed. 
The aim of this study was to provide a detailed snapshot 
of ALF/ALI occurring in North America during preg-
nancy: both pregnancy-associated conditions and those 
conditions that may simply occur during an intrauterine 
pregnancy. We also evaluated the utility of the Swansea 
criteria to differentiate AFLP from other causes of liver 
injury in this relatively large patient cohort.
Patients and Methods
Between January 1998 and November 2017, 3,155 
subjects were registered with ALF or ALI, 70 of whom 
(2.2%) were pregnant or within a week of delivery at the 
time of initial hospital admission and/or study enrollment. 
The ALFSG protocols allow ALI patients to consent for 
themselves, whereas those with ALF, by definition, are 
not capable of consent, requiring the signature of next of 
kin or other legally authorized representative. The study 
protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki. Prior approval was obtained 
from institutional review committees at each of the 
participating sites. For all subjects enrolled, de-identified 
clinical information (as well as serum, plasma, DNA, and 
urine samples) were collected and the data uploaded to an 
electronic database maintained at the Medical University 
of South Carolina (Charleston, SC). Data included 
demographics, etiology, detailed laboratory profiles, 
imaging, and liver biopsy information, where available, 
outcomes at 21 days: death, liver transplantation (LT) or 
“spontaneous” or transplant-free survival (TFS), and fetal 
outcomes as well, where available. Etiological diagnosis 
was initially established by the site principal investigator 
and then later confirmed or revised by a causality adju-
dication committee composed of senior hepatologists. In 
some instances, the committee had access to additional 
serological or biochemical data that were not available 
at the time of initial etiological diagnosis.(13) For exam-
ple, explant or autopsy histology were sought, testing for 
acetaminophen (APAP) protein adducts was performed 
on selected subjects to confirm or deny a suspected diag-
nosis of APAP overdose,(14,15) and further autoimmune 
serologies were systematically performed. As a secondary 
analysis, the causality committee reviewed the evidence 
for PAALD (vs. other etiologies) and determined, where 
possible, whether specific evidence for AFLP or HELLP 
was present. We also reviewed all 70 cases, scoring them 
for the features present that define the Swansea crite-
ria.(7,8) Some of the Swansea criteria, such as uric acid 
measurements, were not routinely available.
StatIStICal aNalySIS
Nonparametric Kruskal-Wallis analysis or Mann-
Whitney U analysis was used for laboratory data and 
Fisher’s exact test for demographic data across the 
various etiological subgroups, using SPSS software 
(v25; IBM Corp., Armonk, NY).
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Among 3,155 prospectively enrolled subjects, 70 
(2.2%) were identified as having ALF or ALI, either 
during pregnancy or in the immediate postpartum 
period, defined as within a week of delivery; 6 were 
initially classified as ALI, including 2 with PAALD 
(AFLP), 2 with APAP, and 2 with other etiolo-
gies. Median age of enrollees was 29; 67.1% were 
white, 22.9% black, 4.3% Asian, and 4.3% Hispanic 
(Table 1). The specific PAALDs (HELLP or AFLP 
or features of both) were recognized and confirmed by 
the adjudication committee in 35 (50%) of the over-
all group. We initially compared PAALD, APAP, and 
the remaining “other” groups (Tables 1 and 2). All 
PAALD patients were enrolled in the study postpar-
tum, given that emergent delivery of the infant invari-
ably had occurred once the obstetrical team became 
aware of a liver-related issue. Median gestational age 
of the PAALD group was 36  weeks (range, 28-39). 
PAALD patients were further adjudicated as AFLP 
(n  =  14), HELLP (n  =  16), and those where delin-
eation was uncertain (n = 5; Tables 3 and 4). APAP 
toxicity was present in 21 (30% of the overall group, 
60% of the remainder). Of these, 4 were considered 
intentional (attempted suicidal ingestion), 15 unin-
tentional (without suicidal intent, typically for pain 
relief ), and 2 were unknown; 11 of the 21 APAP 
cases had received N-acetylcysteine (NAC), route 
unspecified, but virtually all intravenously, and the 
remaining 10 were unknown with regard to NAC. 
Ten non-APAP subjects received NAC, including 
3 AFLP, 2 HELLP and 5 “others.” The remaining 
14 “other” group was comprised of many etiologies: 
autoimmune hepatitis (AIH; 3), drug-induced liver 
injury (DILI; 2), HSV (4), cancer (lymphoma, 2; 
adenocarcinoma, 1), Kikuchi-Fujimoto syndrome 
(1), and thyrotoxicosis (1). No hepatitis A, B, C, or 
E cases were identified. No patients were considered 
to have indeterminate etiology. Follow-up antibody 
taBle 1. Comparison of Demographics, pregnancy Features, and outcomes Between the paalD, apap, and other groups
All AFLP/HELLP APAP Other P Value
N 70 35 21 14
Age, years* 29 (19-43) 31 (19-40) 27 (19-43) 29 (22-38) 0.334
Race† 0.098
White 47 (67.1%) 22 (62.9%) 18 (87.5%) 7 (50.0%)
Black 16 (22.9%) 8 (22.9%) 3 (14.3%) 5 (35.7%)
Other 7 (10.0%) 5 (14.3%) — 2 (14.3%)
Ethnicity 0.584
Hispanic 3 (4.3%) 2 (5.7%) — 1 (7.1%)
Pregnancy/delivery
Gestational age 34 (6-39) 36 (28-39) 30 (6-38) 30 (10-35) <0.001‡
Preeclampsia 13 (41.9%) 11 (68.8%) 2 (28.6%) 0 (0%) 0.002
Eclampsia 3 (12.5%) 2 (15.4%) 1 (16.7%) 0 (0%) 0.796
C-section 34 (75.6%) 25 (89.3%) 4 (44.4%) 5 (35.7%) 0.130
Maternal outcome (21 days)
TFS 48 (68.6%) 23 (65.7%) 17 (81.0%) 8 (57.1%) 0.217
Transplant 11 (15.7%) 6 (17.1%) 1 (4.8%) 4 (28.6%) 0.159
Death 8 (11.4%) 4 (11.4%) 2 (9.5%) 2 (14.3%) 0.777
Unknown 4 (5.7%) 2 (5.7%) 2 (9.5%) —
ALF prognostic index
% TFS 74 (6-97) 72 (17-92) 86 (22-97) 34 (6-77) <0.001‡
Fetal outcome (21 days)
Alive 32 (76.2%) 24 (88.9%) 3 (57.1%) 5 (37.5%)
Dead 10 (23.8%) 3 (11.1%) 4 (42.9%) 3 (625.%)
*Median (range).
†n (%).
‡P value significant at <0.05.
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testing for hepatitis E was performed on 5 patients, 
3 with PAALD, 1 with autoimmune hepatitis, and 1 
with APAP-induced hepatotoxicity. All were negative 
for antibody to hepatitis E virus (anti-HEV) immu-
noglobulin M; 1 (AIH) was positive for anti-HEV 
immunoglobulin G.
Subsequent testing for APAP adducts was per-
formed on 23 subjects, including 17 presumed to have 
APAP toxicity as well as 3 PAALD and 3 “others.” All 
APAP adduct levels were confirmed positive in those 
adjudicated as APAP overdose on clinical grounds; of 
the 6 remaining patients tested, 5 had undetectable 
adducts; however, 1 subject did test positive for APAP 
adducts (see below).
CoMpaRISoN oF ClINICal 
FeatUReS aND oUtCoMeS FoR 
tHe tHRee gRoUpS
Median gestational age of presentation by etiol-
ogy group was PAALD 36  weeks, APAP 30  weeks, 
and other/miscellaneous group 30 weeks. The latter 
two groups included patients from all three trimesters 
(Table 1). Primiparity was present in ~60% of all three 
groups (data not shown). Among PAALD patients, 
57.1% were primiparas, and more than two-thirds expe-
rienced (at least) pre-eclampsia, or eclampsia (68.8% and 
15.4%, respectively). Pre-eclampsia/eclampsia was infre-
quently observed in the non-PAALD groups. PAALD 
taBle 2. Comparison of laboratory Features on admission for the three groups: paalD, apap, and other
All PAALD APAP Other P Value
N 70 35 21 14
Hemoglobin* [g/dL] 9.4 (6.0-14.8) 9.2 (6.7-14.4) 9.8 (7.7-13.9) 9.6 (6.0-14.8) 0.679
WBC* ×103/cu mm 16.5 (2.9-58.0) 20.4 (5.8-58.0) 13.3 (6.5-34.9) 9.6 (2.9-29.1) 0.001†
Platelet* ×103/cu mm 108 (26-452) 84 (26-258) 138 (37-452) 178 (26-343) 0.009†
INR* 1.9 (1.2-12.2) 1.8 (1.2-4.6) 2.1 (1.3-6.0) 2 (1.6-12.2) 0.012†
AST* [IU/L] 524(45-13,288) 117 (45-7,194) 2,368 (73-13,288) 846 (191-8,925) <0.001†
ALT* [IU/L] 340 (3-5,458) 60 (3-1,805) 2,333 (109-5,458) 582 (131-2,572) <0.001†
T Bili* [mg/dL] 7.4 (0.7-42.4) 10.5 (2.5-42.4) 3.3 (0.7-8.6) 11 (1.6-28.5) <0.001†
Creatinine* [mg/dL] 1.7 (0.3-5.8) 2.4 (0.4-5.8) 1.4 (0.3-5.4) 0.7 (0.3-2.7) 0.003†
Ammonia* [μmol/L] 99.5 (21-200) 89 (21-193) 104 (39-200) 166 (120-175) 0.110
Phosphate* [mg/dL] 3.3 (1.0-10.8) 4.0 (1.7-10.8) 2.9 (1.6-8.70) 3.4 (1.0-8.7) 0.032†
Lactate* [mmol/L] 3.6 (0.7-76.6) 3.7 (1.4-76.6) 3.4 (0.9-16.5) 3.5 (0.7-12.1) 0.909
*Median (range).
†P value significant at <0.05; all lab values obtained at study admission.
Abbreviations: T Bili, total bilirubin; WBC, white blood cells.
taBle 3. Comparison of pregnancy Features and outcomes of the aFlp and Hellp groups
All (n = 35) AFLP (n = 14) HELLP (n = 16) Mixed (n = 5) P Value
G1/P1, n (%) 16 (57.1) 6 (60.0) 8 (53.3) 2 (66.7)
Maternal outcome (21 days)
TFS, n (%) 23 (65.7) 10 (71.4) 10 (62.5) 3 (60.0) 0.764
Transplant, n (%) 6 (17.1) 1 (7.1) 4 (25.0) 1 (20.0) 0.469
Death, n (%) 4 (11.4) 2 (14.3) 2 (12.5) 0 0.890
Unknown, n (%) 2 (5.7) 1 (7.1) — 1 (20.0)
ALF prognostic index
% TFS 72 (17-92) 70 (35-85) 74 (19-92) 67 (17-92) 0.669
Fetal outcome (21 days)
Alive. n (%) 24 (88.9) 8 (80.0) 13 (92.9) 3 (100) 0.689
Dead. n (%) 3 (11.1) 2 (20.0) 1 (7.0) —
Limited data were available in some categories, such as fetal outcomes. Percentages reflect, in some instances, incomplete data.
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patients were at or near term and generally considered 
in need of emergency delivery. Thus, 89.3% had under-
gone caesarean section, as compared to 44.4% in the 
APAP group and none in the “other” diagnosis group.
Certain laboratory features varied considerably 
between groups (Table 2): median white blood cell 
counts, bilirubin, and creatinine levels were significantly 
higher, and platelet counts lower, in PAALD patients 
when compared to the other two groups. Hemoglobin, 
INR, ammonia, and lactate values were similar across 
the groups, whereas median aminotransferase, phos-
phate, and bilirubin levels varied by etiological group 
as well. For example, median aspartate and alanine 
aminotransferase (AST/ALT) levels were higher and 
phosphate levels lower in the APAP group compared 
to the PAALD or “other” groups, and bilirubin levels 
likewise were lower in APAP patients, consistent with 
the “hyperacute” clinical course of APAP patients.
Overall survival at 21  days was 58 of 70 (82.8%), 
broken down as follows: spontaneous survival or TFS, 
48 of 70 (68.6 %); 11 of 70 (15.7%) LT, 1 of whom 
died post-LT; and 7 of 70 (12.9%) died without LT. 
Outcome at 21 days was unknown in 4; subsequent 
calculations were based on the total group number of 
70, rather than 66. When outcomes per etiology were 
considered separately (Table 1), APAP toxicity cases 
were associated with better overall survival (85%), 
with fewer requiring LT and fewer deaths. Fetal 
outcomes were available on 42 subjects and differed 
greatly between groups, with survival rates as follows: 
PAALD 96%, APAP 43%, and “other” 55%, again 
reflecting the presentation of the latter two groups at 
almost any time during parturition, including the first 
trimester. We also compared the three groups for pre-
diction of TFS using the ALFSG Prognostic Index 
(Table 1).(17) The three main groups differed signifi-
cantly, with PAALD having a predicted 72% TFS ver-
sus APAP 86% and “other” 34%, each group reflecting 
differing pathogenesis and likelihood of survival.
CoMpaRISoN oF patIeNtS WItH 
aFlp aND Hellp
Criteria available for discerning AFLP from 
HELLP with certainty included the presence of 
microvesicular fat or periportal necrosis on biopsy 
(Fig. 1), or evidence of hepatic rupture, zonal infarc-
tion, or intraperitoneal hemorrhage in HELLP. Less 
taBle 4. Comparison of Clinical and laboratory Features at Study admission Between the aFlp and Hellp groups
All AFLP HELLP Mixed P Value
N 35 14 16 5
Age, years 31 (19-40) 32 (22-40) 30 (23-37) 28 (19-37) 0.272
Hypoglycemic† 14 (66.8%) 7 (50.0%) 6 (60.0%) 1 (100%) 1.000
Pancreatitis† 13 (50.0%) 7 (58.0%) 5 (45.5%) 1 (50.0%) 0.836
Pre-eclampsia† 12 (66.7%) 2 (40.0%) 9 (90.0%) 1 (100%) 0.074
Eclampsia† 2 (13.3%) 1 (25.0%) 0/8 1 (33.3%) 0.200
AFLP on biopsy† 6 (50.0%) 6 (85.7%) 0/4 0/1 0.015
Hemorrhage† 13 (37.1%) 4 (28.5%) 7 (43.8%) 2 (40.0%) 0.721
Hemoglobin* [g/dL] 9.2 (6.7-14.4) 9.2 (6.7-11.5) 9.9 (7.4-14.4) 9 (6.7-9.9) 0.480
WBC* ×103/cu mm 20.4 (5.8-58.0) 21.0 (6.0-58.0) 21.9 (5.87-44.40) 17.4 (8.4-25.4) 0.670
Platelet* ×103/cu mm 84 (26-258) 95.5 (31-203) 82 (26-258) 76 (45-170) 0.644
INR* 1.8 (1.2-4.6) 1.8 (1.2-2.1) 1.7 (1.3-4.6) 1.6 (1.4-2.7) 0.988
AST* [IU/L] 117 (45-7,194) 85.5 (45-165) 642 (48-7,194) 119 (71-177) 0.009†
ALT* [IU/L] 60 (2-1,805) 49 (23-154) 336 (3-1,805) 57 (33-258) 0.045†
T Bili* [mg/dL] 10.5 (2.5-42.4) 8.0 (2.5-25.8) 12.9 (3.6-42.4) 12.4 (3.1-30.5) 0.171
Creatinine* [mg/dL] 2.38 (0.4-5.8) 1.65 (0.5-2.9) 2.85 (0.4-5.8) 2.7 (0.8-3.5) 0.060‡
Ammonia* [μmol/L] 89 (21-193) 107 (72-145) 69 (46-104) 107 (21-193) 0.328
Phosphate* [mg/dL] 4.0 (1.7-10.8) 3.5 (2.1-6.0) 4.7 (1.7-10.8) 6.0 (2.2-7.7) 0.354
Lactate* [mmol/L] 3.7 (1.4-76.6) 5.5 (1.4-76.6) 2.4 (1.7-11.8) 7.8 (3.7-20.1) 0.223
*Median (range).
†n (%).
‡P value significant at <0.05; all lab values obtained at study admission.
Abbreviations: T Bili, total bilirubin; WBC, white blood cells.
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certainty was associated with presence of hypogly-
cemia or pancreatitis (both presumably supporting 
AFLP), or pre-eclampsia or eclampsia, hemolysis, and 
higher aminotransferase elevations (favoring HELLP). 
Despite these limitations, we attempted adjudica-
tion to one or the other diagnosis, AFLP or HELLP 
(Tables 3 and 4). Six of 14 cases designated as AFLP 
had undergone biopsies, all demonstrating microve-
sicular fat. There were no biopsies obtained in the 
HELLP group; 43.8% of the HELLP group had 
evidence of intra-abdominal hemorrhage or hepatic 
hematoma or rupture. After best efforts at adjudica-
tion, there were no differences observed between the 
groups in terms of hemoglobin, platelet count, glucose 
level, ammonia, lactate or phosphate levels, evidence 
or incidence of pancreatitis, or presence of eclampsia/
pre-eclampsia. Groups differed in aminotransferase 
levels, the median AST level in the HELLP group 
being 642  (48-7,194) versus 85  IU/L (45-165) for 
AFLP (P  <  0.009). Serum ALT values were also 
significantly higher in the HELLP group. Lactate 
dehydrogenase and haptoglobin levels as measures of 
hemolysis were not uniformly collected. Comparing 
the three PAALD groups for likelihood of TFS using 
the ALFSG Prognostic Index, there were no apparent 
differences between AFLP, HELLP, and the “mixed” 
group, varying between 74% and 67% (Table 3).
SWaNSea CRIteRIa to 
DIagNoSe aFlp
The Swansea criteria to diagnose AFLP or HELLP, 
developed in 2002,(7) including both clinical symptoms 
and laboratory and imaging findings, were applied 
to this cohort. Table 5 delineates the features of the 
Swansea criteria and how they were met within each 
of the study groups. Six of 14 criteria are required to 
confirm a diagnosis of AFLP in the absence of another 
diagnosis, and two of three HELLP criteria must be 
met for HELLP. We could adequately determine the 
criteria for 66 of 70 patients, but were limited by not 
having available uric acid for most patients. Several 
other criteria (e.g., ultrasound liver imaging) were 
missing in additional cases. Despite these limitations, 
the median number of diagnostic criteria that were 
met, as evidence for AFLP for the PAALD, APAP, 
and “other” groups, were 10, 11, and 12, respectively. 
Thus, we found that 100% of PAALD and 100% 
of APAP patients met Swansea AFLP criteria; 1 
PAALD patient initially diagnosed as ALI only met 
criteria when she became encephalopathic, whereas the 
remaining patients all met criteria at study entry. Even 
within the “other” group, 11 of 14 met Swansea cri-
teria. There were no differences in numbers of AFLP 
or HELLP criteria met between those adjudicated to 
AFLP versus those adjudicated as HELLP; however, 
those not meeting HELLP criteria typically lacked data 
concerning hemolysis (Table 5). There were no evident 
overlaps of etiological diagnoses, with one exception. 
Our adjudication found 1 subject that might have had 
both APAP and HELLP combined, presenting with 
elevated liver enzymes at term, leading to caesarean 
section and a subsequent elevated APAP adduct level; 
for purposes of the study, the patient was considered to 
have HELLP with secondary APAP overdose.
FIg. 1. Pregnancy-associated liver injury. (A) Periportal necrosis 
and hemorrhage in a patient with HELLP syndrome. Centrilobular 
area, upper right, is well preserved (H&E, ×100). (B) Injury 
suggestive of fatty liver disease of pregnancy with evidence of 
microvesicular steatosis (arrow; H&E, ×600). Abbreviation: H&E, 
hematoxylin and eosin.
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DeatH aND tRaNSplaNtatIoN 
IN paalD
Features and outcomes for the 10 patients who died 
or underwent transplant among the PAALD cases were 
carefully reviewed (Table 6). Nine of 10 had undergone 
caesarean section; 6 transplants were performed with 
one posttransplant death, and there were four other 
deaths without transplantation among the PAALD 
group; only 1 of the 4 was listed for transplantation, 
then subsequently removed from listing because of 
cerebral edema: The others had multiple factors, includ-
ing cerebral edema, that precluded listing and appeared 
to develop extrahepatic complications, including pul-
monary emboli, pancreatitis, intra-abdominal infection, 
and seizures. Of note, lactate levels available for 6 of the 
10 were markedly elevated in 4. Individual times from 
delivery to study admission as well as time from study 
admission to outcome are also shown in Table 6. The 6 
transplanted PAALD patients had a median time from 
admission and urgent caesarean section (same day) to 
transfer to the transplant center of 5.0  days, with an 
overall time from delivery to LT of 10.5 days. Median 
time from hospitalization to study admission was 
3.0 days for those who survived without transplantation.
Discussion
Hepatologists are often consulted by the obstet-
rical service when liver disease occurs in pregnancy, 
given that liver diseases unique to pregnancy, though 
rare, carry a poor prognosis.(5,6) Our study encom-
passed not only those with PAALD, but any patient 
presenting with ALF/ALI while pregnant. Our main 
finding was that only 50% of ALFSG registry subjects 
were accounted for by pregnancy-related conditions, 
all occurring peripartum. The remaining cases were 
largely APAP overdoses plus a miscellaneous “other” 
etiologies group. For analysis purposes, we separated 
the patients into these three groups: PAALD, APAP, 
and other.
taBle 5. Fourteen “Swansea” Diagnostic Criteria for aFlp and three for Hellp
APAP (21) Other (14) PAALD (35) AFLP (14) Mixed (5) HELLP (16)
AFLP
1. Vomiting 15 6 20 9 4 7
2. Abdominal pain 9 9 23 7 5 11
3. Polydipsia/polyuria†
4. Elevated transaminases (AST, 42 IU/L) 21 14 35 14 5 15
5. Elevated bilirubin (>14 umol/L or 0.8 mg/dL) 21 14 35 14 5 16
6. Hypoglycemia (<4 mmol/L or 72 mg/dL) 3 4 10 4 2 4
7. Elevated urate (>340 umol/L or 5.7 mg/dL)†
8. Leukocytosis (>11 × 109/L) 13 7 24 13 4 15
9. Elevated ammonia (>47 umol/L) 13 5 25 10 2 13
10. Ascites or bright liver on US 2 7 24 10 4 10
11. Encephalopathy 19 12 32 12 5 15
12. Renal failure (creatinine >1.7 mg/dL or 150 umol/L) 9 4 26 14 5 16
13. Coagulopathy (PT >14 sec; aPTT >34 sec) 21 14 35 14 5 16
14. Microvesicular steatosis on liver biopsy 7 2 10 10 0 0
Met six or more criteria 21 (100%) 11 (78.6%) 34* (97.1%) 14 (100%) 5 (100%) 15* (93.8%)
HELLP
15. Increased AST (>70 IU/mL) 21 14 31 11 5 15
16. Decreased platelets (<100 × 109/L) 5 5 24 7 4 13
17. Hemolysis 13 10 22 9 5 8
Met two or more criteria 16 (76.2%) 10 (71.4%) 29 (82.9%) 10 (71.4%) 5 (100%) 14 (87.5%)
Six or more of the above features qualify for AFLP without explanation of another condition and two of three for HELLP.
Adapted from Ch’ng et al.(7)
*ALI-HELLP subject met five initially, then converted to ALF and met six.
†Information not collected as part of the ALF study.
Abbreviations: US, ultrasound; PT, prothrombin time; aPTT, activated partial thromboplastin time.
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PAALD was associated with fetal survival of 88.9% 
and 88.6% overall maternal survival; however, over-
all maternal TFS was only 68.6%, and 11 received a 
liver graft, 6 with PAALD and 5 in the APAP (1) 
or “other” (4) categories. More transplants occurred in 
those with HELLP (4) than AFLP (1), “mixed” (1), 
although the difference was not statistically signifi-
cant. PAALD is easily recognized in most obstetrical 
settings and is often heralded by pre-eclampsia in the 
third trimester, both in HELLP and AFLP. There is 
currently no specific prognostic score to determine 
outcome or need for transplantation in this patient 
population. A possible prognostic score was pro-
posed recently that includes lactate level and presence 
or absence of hepatic encephalopathy.(16) Although 
we did not collect lactate levels uniformly, several of 
those who died or required transplants among the 10 
PAALD patients had remarkably high lactate levels. If 
larger numbers of patients were available to study, this 
might prove to be a valuable prognostic tool. Median 
lactate levels differed between those who survived and 
those who died or were transplanted (2.9  mmol/L 
[1.7-6.2] vs. 8.8 [1.4-76.7]), but this was not signifi-
cant (P ≤ 0.72). We also examined the performance of 
the ALFSG Prognostic Index in this population.(17) 
Overall, those with TFS had a median likelihood of 
survival of 75% (range, 20-92), whereas those who 
died or required transplantation had a 40% (range, 
17-92) likelihood of survival, (P ≤ 0.049). Future pro-
spective studies might combine lactate levels with the 
ALFSG Prognostic Index specifically for determina-
tion of pregnancy-related outcomes.
For all PAALD patients, the initial hepatology 
consultation and/or transfer to a transplant center 
occurred postpartum; however, this was not always 
promptly carried out. Median time to transfer to 
the transplant center for those who died or required 
transplant was 5.0  days, and time to transplant or 
death was 10.5  days. Recognition of severity of dis-
ease and early transfer may be crucial in preventing 
maternal deaths. It should be recognized that these 
data are biased toward the most severe cases: We 
only observed 35 instances of PAALD over a 22-year 
period in this North American tertiary care study. The 
total number of PAALD cases is difficult to discern, 
but has been estimated at between 1 in 7,000 to 1 in 
16,000 pregnancies.(4,13)
Outcomes among the three groups were poorest 
among the PAALD and “other” groups, the latter 
being a heterogeneous mixture of etiologies, includ-
ing cancer, DILI, AIH, and HSV infection, that all 
have <50% TFS once ALF is present.(12) Virtually 
all the deaths and transplants occurred within these 
two groups. Table 6 details some of the features of 
the four deaths and six transplants among the 35 
PAALD patients. The deaths were equally distrib-
uted between AFLP and HELLP diagnoses. Causes 
of death appeared largely to be extrahepatic in ori-
gin, whereas those receiving transplants had demon-
strated ongoing liver injury postpartum but survived 
long enough to receive a graft. Delayed recognition 
of ALF and its consequences may lead to late referral 
that may contribute to these unfortunate and possibly 
avoidable deaths.
A committee of senior hepatologists reviewed all 
cases in the series, some of which lacked complete 
information and most of which did not include 
liver biopsies, to help categorize the PAALD cases 
as AFLP and HELLP. Although these are thought 
to be two distinct clinical syndromes with unique 
clinical and histological features,(18) there is a clear 
overlap of presenting features, which has long been 
recognized.(19) Diagnosis on clinical grounds is 
challenging, given that imaging is not definitive and 
clinical symptoms and serological data often non-
specific.(20) Only a biopsy showing periportal necro-
sis (HELLP) or microvesicular fat (AFLP) (Fig. 1) 
or evidence of hepatic hematoma or rupture with 
intra-abdominal hemorrhage provided any certainty 
in differentiating HELLP and AFLP. Little has 
been written about use of imaging to distinguish the 
two; however, nonalcoholic fatty liver might also be 
present, in addition to possible microvesicular fat.(21) 
The main value of hepatic imaging is to exclude 
intra- or extrahepatic hemorrhage. More recently, 
magnetic resonance-based proton-density fat frac-
tion testing has shown to be a very sensitive and 
specific means of detecting steatosis in the liver in a 
quantitative manner, but this technique has not been 
applied to ALF patients with suspected AFLP, to 
our knowledge.(22) Given that biopsy is rarely per-
formed, certainty of diagnosis, in many cases, will 
continue to be limited, given the number of features 
shared by both conditions.
Likewise, we could not identify any additional spe-
cific clinical features that assisted in clarifying either 
diagnosis. Only 10 of the 70 fulfilled criteria for 
ALI (INR > 2.0 and no encephalopathy), 4 of whom 
Hepatology, Vol. 72, No. 4, 2020 CASEY ET AL.
1375
converted to ALF thereafter; we did not analyze 
this group separately because of its small size. Pre-
eclampsia, eclampsia, platelet counts, and presence of 
pancreatitis or hypoglycemia have all been alleged to 
be somewhat specific, but were not more common in 
one condition or the other in the present study. We 
did find that aminotransferases were significantly 
higher in HELLP than in those adjudicated cases 
with AFLP.
We were also intrigued to test whether the Swansea 
criteria applied to this patient population of severely ill 
postpartum patients could validate their use for clini-
cians. We found that most Swansea features were also 
present in those with ALF of any cause. All patients 
met criteria save 1, indicating that the Swansea crite-
ria truly represent features common to ALF patients, 
but not specifically to AFLP patients.(3) Whereas 
most APAP cases are readily recognized and would be 
excluded from Swansea consideration given that the 
criteria also mention absence of another cause, some 
APAP cases and many ALF etiologies are not so eas-
ily discerned.(23) In our hands, the Swansea criteria, 
including so many nonspecific items, failed to provide 
any clear delineation between AFLP and HELLP, 
with a low specificity and positive predictive value 
among pregnant ALI and ALF patients. It remains 
unclear whether these very severe examples of AFLP 
and HELLP can be reasonably separated using clinical 
or biochemical criteria.(13,24) Given these uncertain-
ties, we wonder whether diagnoses in recent studies 
based on pooled data, such as the Scientific Registry 
of Transplant Recipients, can be trusted given that 
histological diagnosis is so rarely available.(25)
Thus, from clinical information alone and with-
out a biopsy, an accurate diagnosis is hard to achieve. 
Should a liver biopsy be performed in all cases? This 
is doubtful—we question the risk of liver biopsy 
in these patients, most of whom have diminished 
platelet counts. Whether there are, in fact, any clin-
ical differences in management that follow from 
determining whether AFLP or HELLP is found 
remains to be seen, at least for full-term pregnan-
cies.(3) Evidence of hepatic hemorrhage or rupture, 
of course, mandates steps to control the bleeding.
APAP toxicity, the second-largest group after 
PAALD, represents the most frequent cause of ALF 
in the United States and Europe.(26,27) An overdose 
may occur during any trimester, some representing 
suicide attempts and others inadvertent excessive use 
for relief of symptoms(28); in the present series, most 
were thought to be unintentional overdoses. Overall, 
outcomes remain quite good, although fetal demise 
and occasional maternal deaths do occur, in similar 
numbers to those women not pregnant at the time 
of the incident. In the current series, at least 11 of 
the 21 APAP cases received NAC with information 
lacking on the remaining subjects. Fetal outcomes did 
not appear to be related to the route or duration of 
NAC administration (data not shown). Confirmatory 
testing for serum APAP-protein adducts(14,15) was 
undertaken in 17 of the 21 cases, and a level exceed-
ing 1 nmol/mL was present in all subjects tested. 
One additional positive adduct subject represented a 
patient at term who likely had taken an unintentional 
overdose, but underwent emergent delivery, given her 
elevated liver tests and term status at 38 weeks. That 
most cases appeared to be unintentional suggests 
that they should be avoidable with better consumer/ 
prenatal education.(13)
The “other” group was of interest in that no single 
diagnosis predominated; 3 HSV-hepatitis cases were 
found, as well as several other causes generally asso-
ciated with poor outcomes.(9-11) We were surprised to 
find no cases of viral hepatitis A through E in preg-
nancy during the 22 years of this study, given that ear-
lier studies featured viral hepatitis (VH) as the most 
common cause of jaundice in pregnancy.(29,30) The 
low incidence of VH in our cohort may be attribut-
able to previous hepatitis A and B vaccinations among 
younger American patients.(31,32) Hepatitis E, long 
recognized as particularly prevalent in the developing 
world, was also not noted in the present study, likely 
because of the different genotypes and disease patterns 
observed in North America that do not seem prone to 
severe liver injury.(33,34) We also did not identify any 
patients with intrahepatic cholestasis of pregnancy 
leading to ALF or ALI, given that this group does 
not typically lead to severe liver cell injury, though it 
may occur in the third trimester.(35)
This study is limited by its retrospective nature, 
although the data were collected in a prospective fash-
ion. We identified and enrolled those cases of ALF and 
ALI of all etiologies that came to the attention of liver 
specialists in tertiary care centers. In some instances, 
information, such as peripartum blood pressures, was 
not captured. In other instances, details of fetal out-
come were unknown. An additional limitation of our 
study was the lack of genetic testing of the mothers and 
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infants with PAALD for long-chain 3-hydroxyacyl- 
CoA dehydrogenase (LCHAD) mutations that have 
been identified in up to 20% of women with AFLP.(36) 
However, more recent studies have identified that some 
LCHAD mutations may be over-represented in preg-
nant women with HELLP and pre-eclampsia.(37,38) 
Testing was not feasible because of the lack of available 
DNA samples in many of the subjects.
In conclusion, half of the women who develop 
ALF or ALI during pregnancy are not suffering 
from a disease directly related to the pregnancy 
itself, but rather from other diseases that are rela-
tively common in this age group, but not currently 
including the common varieties of VH. Maternal 
outcomes are generally favorable for both PAALD 
and APAP, but less so for those with other etiolo-
gies. In contrast, fetal outcomes are not as satisfac-
tory, particularly for the “other” and APAP causes, 
given that their occurrence across all trimesters lim-
its fetal maturity. Recognition of PAALD in the 
third trimester is the first step to diagnosis and ini-
tial treatment. Hepatologists are typically consulted 
when the associated liver disease does not resolve 
immediately postpartum. Early referral and trans-
plant consideration are mandated as it is for anyone 
with signs and symptoms of ALF.
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